JP2023524997A5 - - Google Patents
Info
- Publication number
- JP2023524997A5 JP2023524997A5 JP2022567343A JP2022567343A JP2023524997A5 JP 2023524997 A5 JP2023524997 A5 JP 2023524997A5 JP 2022567343 A JP2022567343 A JP 2022567343A JP 2022567343 A JP2022567343 A JP 2022567343A JP 2023524997 A5 JP2023524997 A5 JP 2023524997A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- nos
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020806P | 2020-05-06 | 2020-05-06 | |
| US63/020,806 | 2020-05-06 | ||
| PCT/US2021/030773 WO2021226163A2 (en) | 2020-05-06 | 2021-05-05 | Antibodies targeting clec12a and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524997A JP2023524997A (ja) | 2023-06-14 |
| JP2023524997A5 true JP2023524997A5 (enExample) | 2024-05-16 |
Family
ID=78468386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567343A Pending JP2023524997A (ja) | 2020-05-06 | 2021-05-05 | Ｃｌｅｃ１２ａを標的とする抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230220084A1 (enExample) |
| EP (1) | EP4146704A4 (enExample) |
| JP (1) | JP2023524997A (enExample) |
| KR (1) | KR20230008157A (enExample) |
| CN (1) | CN115697402A (enExample) |
| AU (1) | AU2021267023A1 (enExample) |
| BR (1) | BR112022022418A2 (enExample) |
| CA (1) | CA3177818A1 (enExample) |
| IL (1) | IL297950A (enExample) |
| MX (1) | MX2022013882A (enExample) |
| WO (1) | WO2021226163A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EP4291233A4 (en) * | 2021-02-10 | 2025-05-21 | Wugen, Inc. | POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| GB202214132D0 (en) * | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2441838A3 (en) * | 2006-01-24 | 2013-07-10 | Domantis Limited | Fusion proteins that contain natural junctions |
| US8163279B2 (en) * | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| HUE042040T2 (hu) * | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| US10501545B2 (en) * | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
| WO2017011342A1 (en) * | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| DK3515478T3 (da) * | 2016-09-21 | 2024-05-21 | Nextcure Inc | Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf |
| EA202090718A1 (ru) * | 2017-09-14 | 2020-07-01 | Драгонфлай Терапьютикс, Инк. | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) |
| EP3850013A4 (en) * | 2018-09-10 | 2022-10-05 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF |
-
2021
- 2021-05-05 JP JP2022567343A patent/JP2023524997A/ja active Pending
- 2021-05-05 KR KR1020227042237A patent/KR20230008157A/ko active Pending
- 2021-05-05 CN CN202180033626.0A patent/CN115697402A/zh active Pending
- 2021-05-05 AU AU2021267023A patent/AU2021267023A1/en not_active Abandoned
- 2021-05-05 WO PCT/US2021/030773 patent/WO2021226163A2/en not_active Ceased
- 2021-05-05 CA CA3177818A patent/CA3177818A1/en active Pending
- 2021-05-05 US US17/923,411 patent/US20230220084A1/en active Pending
- 2021-05-05 EP EP21799694.1A patent/EP4146704A4/en active Pending
- 2021-05-05 IL IL297950A patent/IL297950A/en unknown
- 2021-05-05 MX MX2022013882A patent/MX2022013882A/es unknown
- 2021-05-05 BR BR112022022418A patent/BR112022022418A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023524997A5 (enExample) | ||
| JP7749643B2 (ja) | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 | |
| JP2022551757A5 (enExample) | ||
| JP2024537772A5 (enExample) | ||
| JP2021526844A5 (enExample) | ||
| IL311600A (en) | Antibodies targeting BAFF-R and their use | |
| IL317912A (en) | A combined chimeric antigen receptor targeting CD19 and CD20 and its applications | |
| CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| JP7854121B2 (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| CA3091424A1 (en) | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use | |
| CA3091764A1 (en) | Antibody variable domains targeting cd33, and use thereof | |
| AU2016359683A1 (en) | Heterodimeric antibodies that bind CD3 and CD38 | |
| WO2017142928A1 (en) | Ror1-binding molecules, and methods of use thereof | |
| TW201702265A (zh) | 結合lag-3的分子和其使用方法 | |
| JP2023546766A5 (enExample) | ||
| JP2023546764A5 (enExample) | ||
| JP2022520455A5 (enExample) | ||
| JP2024534847A5 (enExample) | ||
| JP2023525778A5 (enExample) | ||
| EP3558368A1 (en) | Adam9-binding molecules, and methods of use thereof | |
| JP2023553390A5 (enExample) | ||
| AU2017278329A1 (en) | Methods for the use of CD32B x CD79B-binding molecules in the treatment of inflammatory diseases and disorders | |
| JP2022508529A (ja) | 二重標的抗原結合分子 | |
| TW202221015A (zh) | 單一及雙靶定配體誘導之t細胞銜接體組合物 | |
| JP2021524451A (ja) | 最適化済みｇｐ４１結合分子及びその使用 |